ALK and neuroblastoma: Genomics analyses of relapsed neuroblastomas indicate that such treatments could include inhibition of ALK and the RAS-MAPK pathway, YAP inhibition and/or pathways involved in EMT (Eleveld et al. 2015; Padovan-Merhar et al. 2016; Schramm et al. 2015).